Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 119

1.

The MISCAN-Fadia continuous tumor growth model for breast cancer.

Tan SY, van Oortmarssen GJ, de Koning HJ, Boer R, Habbema JD.

J Natl Cancer Inst Monogr. 2006;(36):56-65.

PMID:
17032895
[PubMed - indexed for MEDLINE]
2.

Modeling the impact of treatment and screening on U.S. breast cancer mortality: a Bayesian approach.

Berry DA, Inoue L, Shen Y, Venier J, Cohen D, Bondy M, Theriault R, Munsell MF.

J Natl Cancer Inst Monogr. 2006;(36):30-6.

PMID:
17032892
[PubMed - indexed for MEDLINE]
3.

A stochastic simulation model of U.S. breast cancer mortality trends from 1975 to 2000.

Plevritis SK, Sigal BM, Salzman P, Rosenberg J, Glynn P.

J Natl Cancer Inst Monogr. 2006;(36):86-95.

PMID:
17032898
[PubMed - indexed for MEDLINE]
4.

Impact of adjuvant therapy and mammography on U.S. mortality from 1975 to 2000: comparison of mortality results from the cisnet breast cancer base case analysis.

Cronin KA, Feuer EJ, Clarke LD, Plevritis SK.

J Natl Cancer Inst Monogr. 2006;(36):112-21.

PMID:
17032901
[PubMed - indexed for MEDLINE]
5.

The SPECTRUM population model of the impact of screening and treatment on U.S. breast cancer trends from 1975 to 2000: principles and practice of the model methods.

Mandelblatt J, Schechter CB, Lawrence W, Yi B, Cullen J.

J Natl Cancer Inst Monogr. 2006;(36):47-55.

PMID:
17032894
[PubMed - indexed for MEDLINE]
6.

The University of Rochester model of breast cancer detection and survival.

Hanin LG, Miller A, Zorin AV, Yakovlev AY.

J Natl Cancer Inst Monogr. 2006;(36):66-78.

PMID:
17032896
[PubMed - indexed for MEDLINE]
7.

Modeling the impact of adjuvant therapy and screening mammography on U.S. breast cancer mortality between 1975 and 2000: introduction to the problem.

Feuer EJ.

J Natl Cancer Inst Monogr. 2006;(36):2-6. Review. No abstract available.

PMID:
17032887
[PubMed - indexed for MEDLINE]
8.

Modeling cancer natural history, epidemiology, and control: reflections on the CISNET breast group experience.

Habbema JD, Schechter CB, Cronin KA, Clarke LD, Feuer EJ.

J Natl Cancer Inst Monogr. 2006;(36):122-6. No abstract available.

PMID:
17032902
[PubMed - indexed for MEDLINE]
9.

Impact of mammography on U.S. breast cancer mortality, 1975-2000: are intermediate outcome measures informative?

Habbema JD, Tan SY, Cronin KA.

J Natl Cancer Inst Monogr. 2006;(36):105-11.

PMID:
17032900
[PubMed - indexed for MEDLINE]
10.

Estimation of natural history parameters of breast cancer based on non-randomized organized screening data: subsidiary analysis of effects of inter-screening interval, sensitivity, and attendance rate on reduction of advanced cancer.

Wu JC, Hakama M, Anttila A, Yen AM, Malila N, Sarkeala T, Auvinen A, Chiu SY, Chen HH.

Breast Cancer Res Treat. 2010 Jul;122(2):553-66. doi: 10.1007/s10549-009-0701-x. Epub 2010 Jan 7.

PMID:
20054645
[PubMed - indexed for MEDLINE]
11.

Additional common inputs for analyzing impact of adjuvant therapy and mammography on U.S. mortality.

Cronin KA, Mariotto AB, Clarke LD, Feuer EJ.

J Natl Cancer Inst Monogr. 2006;(36):26-9. Review.

PMID:
17032891
[PubMed - indexed for MEDLINE]
12.

Effect of screening and adjuvant therapy on mortality from breast cancer.

Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, Mandelblatt JS, Yakovlev AY, Habbema JD, Feuer EJ; Cancer Intervention and Surveillance Modeling Network (CISNET) Collaborators.

N Engl J Med. 2005 Oct 27;353(17):1784-92.

PMID:
16251534
[PubMed - indexed for MEDLINE]
Free Article
13.

A stochastic model for predicting the mortality of breast cancer.

Lee S, Zelen M.

J Natl Cancer Inst Monogr. 2006;(36):79-86.

PMID:
17032897
[PubMed - indexed for MEDLINE]
14.

Advanced breast cancer and breast cancer mortality in randomized controlled trials on mammography screening.

Autier P, Héry C, Haukka J, Boniol M, Byrnes G.

J Clin Oncol. 2009 Dec 10;27(35):5919-23. doi: 10.1200/JCO.2009.22.7041. Epub 2009 Nov 2. Review.

PMID:
19884547
[PubMed - indexed for MEDLINE]
15.
16.

A comparative review of CISNET breast models used to analyze U.S. breast cancer incidence and mortality trends.

Clarke LD, Plevritis SK, Boer R, Cronin KA, Feuer EJ.

J Natl Cancer Inst Monogr. 2006;(36):96-105. Review.

PMID:
17032899
[PubMed - indexed for MEDLINE]
17.

The Wisconsin Breast Cancer Epidemiology Simulation Model.

Fryback DG, Stout NK, Rosenberg MA, Trentham-Dietz A, Kuruchittham V, Remington PL.

J Natl Cancer Inst Monogr. 2006;(36):37-47.

PMID:
17032893
[PubMed - indexed for MEDLINE]
18.

Results of the Two-County trial of mammography screening are not compatible with contemporaneous official Swedish breast cancer statistics.

Zahl PH, Gøtzsche PC, Andersen JM, Maehlen J.

Dan Med Bull. 2006 Nov;53(4):438-40.

PMID:
17150148
[PubMed - indexed for MEDLINE]
19.

Systemic treatments for women with breast cancer: outcome with relation to screening for the disease.

Goldhirsch A, Colleoni M, Domenighetti G, Gelber RD.

Ann Oncol. 2003 Aug;14(8):1212-4. Review.

PMID:
12881381
[PubMed - indexed for MEDLINE]
Free Article
20.

Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality.

Munoz D, Near AM, van Ravesteyn NT, Lee SJ, Schechter CB, Alagoz O, Berry DA, Burnside ES, Chang Y, Chisholm G, de Koning HJ, Ali Ergun M, Heijnsdijk EA, Huang H, Stout NK, Sprague BL, Trentham-Dietz A, Mandelblatt JS, Plevritis SK.

J Natl Cancer Inst. 2014 Sep 24;106(11). pii: dju289. doi: 10.1093/jnci/dju289. Print 2014 Nov.

PMID:
25255803
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk